Quality of Reporting on the Evaluation of Risk Minimization Programs: A Systematic Review
- 4 February 2020
- journal article
- review article
- Published by Springer Science and Business Media LLC in Drug Safety
- Vol. 43 (5), 427-446
- https://doi.org/10.1007/s40264-020-00905-8
Abstract
Risk minimization programs are interventions mandated by regulatory agencies to ensure that benefits of pharmaceutical products outweigh risks. Many regulatory agencies require programs be evaluated for effectiveness; however, the quality of evidence has limited the ability to definitively determine if programs improve drug safety.This publication has 65 references indexed in Scilit:
- Differential Impact of Two Risk Communications on Antipsychotic Prescribing to People with Dementia in Scotland: Segmented Regression Time Series Analysis 2001–2011PLOS ONE, 2013
- An evaluation of asthma medication utilization for risk evaluation and mitigation strategies (REMS) in the United States: 2005–2011Journal of Asthma, 2013
- The Additional Value of an E-Mail to Inform Healthcare Professionals of a Drug Safety Issue: A Randomized Controlled Trial in the NetherlandsDrug Safety, 2013
- A 9-year evaluation of temporal trends in alosetron postmarketing safety under the risk management programTherapeutic Advances in Gastroenterology, 2013
- Complications of BCG vaccine SSI® recent story and risk management plan: the French experiencePharmacoepidemiology and Drug Safety, 2012
- Writing implementation research grant proposals: ten key ingredientsImplementation Science, 2012
- Evaluation of the effectiveness of risk minimization measuresPharmacoepidemiology and Drug Safety, 2012
- Public Pharmacovigilance CommunicationDrug Safety, 2010
- A human factors engineering paradigm for patient safety: designing to support the performance of the healthcare professional: Figure 1BMJ Quality & Safety, 2006